Final results of this phase II study [43] showed 28% ORR and 73% of dose reduction rate (DRR) due to AEs in the 26 patients with RET-rearrangement NSCLC, that have been treated with cabozantinib. Here, RET is linked to non-small cell lung carcinoma.